Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRN015
MIFTS: 50

Bronchiolo-Alveolar Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bronchiolo-Alveolar Adenocarcinoma

About this section

MalaCards integrated aliases for Bronchiolo-Alveolar Adenocarcinoma:

Name: Bronchiolo-Alveolar Adenocarcinoma 12 15
Bronchioloalveolar Carcinoma 12 17
Minimally Invasive Lung Adenocarcinoma 12
Adenocarcinoma, Bronchiolo-Alveolar 45
Bronchioloalveolar Adenocarcinoma 74
Bronchioalveolar Lung Carcinoma 12
Carcinoma Bronchioloalveolar 56

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4926
MeSH 45 D002282
NCIt 51 C2923
SNOMED-CT 69 36310008
UMLS 74 C0007120
Sources

Summaries for Bronchiolo-Alveolar Adenocarcinoma

About this section
Disease Ontology : 12 A lung adenocarcinoma characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension.

MalaCards based summary : Bronchiolo-Alveolar Adenocarcinoma, also known as bronchioloalveolar carcinoma, is related to mucinous bronchioloalveolar adenocarcinoma and in situ pulmonary adenocarcinoma, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Bronchiolo-Alveolar Adenocarcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Gefitinib and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and thyroid, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Sources

Related Diseases for Bronchiolo-Alveolar Adenocarcinoma

About this section

Diseases related to Bronchiolo-Alveolar Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 mucinous bronchioloalveolar adenocarcinoma 32.2 CDX2 KRT20 KRT7 NKX2-1
2 in situ pulmonary adenocarcinoma 32.0 ASPH EGFR HYAL2
3 adenocarcinoma 30.4 CDH1 EGFR KRAS MUC4
4 sclerosing hemangioma 30.3 KRT7 NKX2-1
5 papillary adenocarcinoma 30.2 CDH1 KRT7 NKX2-1
6 solid adenocarcinoma with mucin production 30.1 KRT7 MUC6 NKX2-1
7 small cell cancer of the lung 30.1 EGFR KRT20 KRT7 NKX2-1
8 appendix adenocarcinoma 30.0 CDX2 KRT20 KRT7
9 adenocarcinoma in situ 29.7 CDX2 KRAS KRT20 KRT7
10 thyroid cancer 29.6 CDH1 EGFR KRAS NKX2-1
11 mucinous adenocarcinoma 29.3 CDX2 EGFR KRAS KRT20 KRT7 NKX2-1
12 lung cancer 28.8 CDH1 EGFR FHIT KRAS KRT20 KRT7
13 lung cancer susceptibility 3 28.4 CDH1 CDX2 EGFR FHIT KRAS KRT20
14 mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma 11.5
15 nonmucinous bronchioloalveolar adenocarcinoma 11.5
16 acneiform dermatitis 10.4 EGFR KRAS
17 basaloid squamous cell carcinoma 10.4 EGFR KRT7
18 atypical choroid plexus papilloma 10.4 KRT7 NKX2-1
19 rete testis neoplasm 10.4 KRT20 NKX2-1
20 paget disease, extramammary 10.4 KRT20 KRT7
21 immune system organ benign neoplasm 10.4 KRT20 KRT7
22 eccrine sweat gland neoplasm 10.4 KRT20 KRT7
23 thymus lipoma 10.4 KRT20 KRT7
24 dermoid cyst 10.4 KRT20 KRT7
25 mucinous cystadenocarcinoma 10.4 KRT20 KRT7
26 cystadenofibroma 10.4 KRT20 KRT7
27 pancreatic mucinous cystadenoma 10.4 KRT20 KRT7
28 benign breast adenomyoepithelioma 10.4 EGFR KRT7
29 pneumonia 10.3
30 paronychia 10.3 EGFR KRAS
31 oncocytic breast carcinoma 10.3 EGFR KRT7
32 lipid-rich carcinoma 10.3 CDH1 EGFR
33 inflammatory breast carcinoma 10.3 CDH1 EGFR
34 ovarian germ cell teratoma 10.3 KRT7 NKX2-1
35 ovarian germ cell cancer 10.3 KRT7 NKX2-1
36 cystic basal cell carcinoma 10.3 KRT20 KRT7
37 seminal vesicle adenocarcinoma 10.3 KRT20 KRT7
38 transverse colon cancer 10.3 KRT20 KRT7
39 malignant syringoma 10.3 KRT20 KRT7
40 papillary adenoma 10.3 KRT7 NKX2-1
41 colloid adenoma 10.3 KRT20 NKX2-1
42 breast myoepithelial neoplasm 10.3 CDH1 KRT7
43 superior mesenteric artery syndrome 10.3 CDX2 MUC6
44 papillary transitional carcinoma 10.3 KRT20 KRT7
45 eyelid carcinoma 10.3 KRT20 KRT7
46 krukenberg carcinoma 10.3 KRT20 KRT7
47 ovary neuroendocrine neoplasm 10.3 CDX2 KRT7
48 lung adenoid cystic carcinoma 10.3 KRAS NKX2-1
49 intratubular embryonal carcinoma 10.3 KRT20 KRT7
50 vulval paget's disease 10.2 KRT20 KRT7

Graphical network of the top 20 diseases related to Bronchiolo-Alveolar Adenocarcinoma:



Diseases related to Bronchiolo-Alveolar Adenocarcinoma
Sources

Symptoms & Phenotypes for Bronchiolo-Alveolar Adenocarcinoma

About this section

UMLS symptoms related to Bronchiolo-Alveolar Adenocarcinoma:


fever, dyspnea, hemoptysis, coughing

MGI Mouse Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 ASPH CDH1 CDX2 EGFR FHIT KRAS
2 homeostasis/metabolism MP:0005376 9.61 ASPH CDH1 CDX2 EGFR FHIT HYAL2
3 neoplasm MP:0002006 9.17 ASPH CDH1 CDX2 EGFR FHIT KRAS
Sources

Drugs & Therapeutics for Bronchiolo-Alveolar Adenocarcinoma

About this section

Drugs for Bronchiolo-Alveolar Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
3
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
7
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
10
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
11
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
12
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
13
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
15
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
16 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
17 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
18 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
19 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
22 Etoposide phosphate Phase 3,Phase 2,Phase 1
23 Folate Phase 3,Phase 2,Phase 1
24 Vitamin B Complex Phase 3,Phase 2,Phase 1
25 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
26 Vitamin B9 Phase 3,Phase 2,Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
31 Antiviral Agents Phase 3,Phase 2,Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
34 Immunoglobulins Phase 2, Phase 3,Phase 1
35 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
36 Antibodies Phase 2, Phase 3,Phase 1
37 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
38 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
39 Mitogens Phase 3,Phase 2
40 Epoetin alfa Phase 3 113427-24-0
41 Hematinics Phase 3,Phase 2
42 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
43
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
44
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
45
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
46
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
47
Promethazine Approved, Investigational Phase 2 60-87-7 4927
48
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
49
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
50
Lomustine Approved, Investigational Phase 2 13010-47-4 3950

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
4 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
6 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
7 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
8 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
9 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
12 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
17 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
18 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
19 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma Completed NCT00430261 Phase 2 sunitinib
20 Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00029003 Phase 2 gefitinib
21 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Completed NCT00118144 Phase 2 bortezomib
22 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Completed NCT00103207 Phase 2
23 Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
24 Paclitaxel in Treating Patients With Lung Cancer Completed NCT00002972 Phase 2 paclitaxel
25 S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00002969 Phase 2 paclitaxel
26 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00416650 Phase 2 erlotinib hydrochloride
27 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
28 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
29 Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00411047 Phase 2 gefitinib
30 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Completed NCT00103116 Phase 2
31 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
32 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2
33 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
34 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
35 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
36 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers Completed NCT01344824 Phase 2 carboplatin;erlotinib hydrochloride;pemetrexed disodium
37 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00553462 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
38 Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00425646 Phase 2 imatinib mesylate
39 Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00970684 Phase 2 docetaxel;gemcitabine hydrochloride
40 Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
41 Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy Completed NCT00365547 Phase 2 topotecan hydrochloride
42 Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC Completed NCT00354549 Phase 2 bevacizumab + erlotinib hydrochloride;gemcitabine hydrochloride + cisplatin or carboplatin
43 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00234052 Phase 2 carboplatin;pemetrexed
44 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00117962 Phase 2 carboplatin;pemetrexed disodium
45 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
46 Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00081302 Phase 2 carboplatin;paclitaxel
47 Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed NCT00033553 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
48 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
49 Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
50 Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT01302808 Phase 1, Phase 2 erlotinib hydrochloride;romidepsin

Search NIH Clinical Center for Bronchiolo-Alveolar Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, bronchiolo-alveolar

Sources

Genetic Tests for Bronchiolo-Alveolar Adenocarcinoma

About this section
Sources

Anatomical Context for Bronchiolo-Alveolar Adenocarcinoma

About this section

MalaCards organs/tissues related to Bronchiolo-Alveolar Adenocarcinoma:

42
Lung, Breast, Thyroid, Brain, Colon, Appendix, Endothelial
Sources

Publications for Bronchiolo-Alveolar Adenocarcinoma

About this section

Articles related to Bronchiolo-Alveolar Adenocarcinoma:

(show top 50) (show all 351)
# Title Authors Year
1
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. ( 28801183 )
2018
2
Image Diagnosis: Bronchioloalveolar Carcinoma Presenting as Unilateral "Crazy-Paving" Pattern on High-Resolution Computed Tomography. ( 27083012 )
2016
3
Case report of the bronchioloalveolar carcinoma. ( 25709995 )
2015
4
The Demise of the Term Bronchioloalveolar Carcinoma. ( 26230592 )
2015
5
Bronchioloalveolar carcinoma: time for a new term. ( 24012240 )
2014
6
Congenital cystic adenomatoid malformation with associated mucinous bronchioloalveolar carcinoma in a neonate. ( 24093545 )
2014
7
Bronchioloalveolar carcinoma in a juvenile rhadomyosarcoma patient. ( 24570868 )
2014
8
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma. ( 24747679 )
2014
9
Significance of the histological and ultrastructural features of elastic fibers in diagnosis of bronchioloalveolar carcinoma. ( 24867516 )
2014
10
Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity. ( 25654480 )
2014
11
A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung. ( 23617234 )
2013
12
A favorable response to cisplatin, pemetrexed and bevacizumab in two cases of invasive mucinous adenocarcinoma formerly known as pneumonic-type mucinous bronchioloalveolar carcinoma. ( 24334585 )
2013
13
Bronchioloalveolar carcinoma as a second malignancy in a pediatric osteosarcoma survivor: case report. ( 23758793 )
2013
14
Global gene expression differentiating pure bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar carcinoma features. ( 22864788 )
2013
15
Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis. ( 23286648 )
2013
16
Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. ( 23415808 )
2013
17
Bronchioloalveolar carcinoma in a young patient: a case report. ( 23490086 )
2013
18
Imaging of bronchioloalveolar carcinoma in the mice with the αⅤβ3 integrin-targeted tracer (99m)Tc-RGD-4CK. ( 23867618 )
2013
19
Well-differentiated adenocarcinoma-bronchioloalveolar carcinoma-in situ adenocarcinoma: a conundrum. ( 23939151 )
2013
20
Clinical characteristics of patients with bronchioloalveolar carcinoma: a retrospective study of 44 cases. ( 23992004 )
2013
21
Mucinous bronchioloalveolar carcinoma with K-ras mutation arising in type 1 congenital cystic adenomatoid malformation: a case report with review of the literature. ( 24228126 )
2013
22
Former mucinous bronchioloalveolar carcinoma revisited. ( 24369471 )
2013
23
Chronic exposure to particles caused bronchioloalveolar carcinoma in a patient with cryptogenic organizing pneumonia evaluated by elemental analysis. ( 21675931 )
2012
24
Urticaria as the initial presentation of early stage bronchioloalveolar carcinoma: a case report. ( 22884079 )
2012
25
Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene? ( 22296236 )
2012
26
Severe bronchorrhea in a patient with bronchioloalveolar carcinoma. ( 22315118 )
2012
27
Aspects of bronchioloalveolar carcinoma and of adenocarcinoma with a bronchioloalveolar component: CT findings. ( 22576431 )
2012
28
Bilateral lung transplant for bronchioloalveolar carcinoma: first case in China. ( 22758387 )
2012
29
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial. ( 22767177 )
2012
30
A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. ( 22842620 )
2012
31
Positron emission tomography in bronchioloalveolar carcinoma of the lung. ( 23017426 )
2012
32
Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case-control studies in the International Lung Cancer Consortium (ILCCO). ( 21072579 )
2011
33
Dramatic response to pemetrexed in a patient with pneumonic-type mucinous bronchioloalveolar carcinoma. ( 21252722 )
2011
34
Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity. ( 21317746 )
2011
35
Micronodular pattern caused by bronchioloalveolar carcinoma. ( 21419558 )
2011
36
Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). ( 21422434 )
2011
37
Bronchioloalveolar carcinoma. ( 21500124 )
2011
38
Bronchorrhea in bronchioloalveolar carcinoma. ( 21555870 )
2011
39
Risk of bronchioloalveolar carcinoma in patients with human T-cell lymphotropic virus type 1 (HTLV-I): case-control study results. ( 21587123 )
2011
40
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). ( 21716143 )
2011
41
LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma. ( 21816872 )
2011
42
Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptor. ( 21911454 )
2011
43
How many adenocarcinoma lung cancers come from bronchioloalveolar carcinoma? ( 27755811 )
2011
44
Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs. ( 20688833 )
2010
45
Bronchioloalveolar carcinoma and the significance of invasion: predicting biologic behavior. ( 20923299 )
2010
46
Surgical resection for patients with mucinous bronchioloalveolar carcinoma. ( 21029945 )
2010
47
Cytodiagnostic aspects of bronchioloalveolar carcinoma manifesting with small cell morphology on respiratory specimens: a case report. ( 21053590 )
2010
48
Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target? ( 21138169 )
2010
49
Bronchioloalveolar carcinoma: a translational perspective. ( 21138171 )
2010
50
Solitary nodular pure bronchioloalveolar carcinoma. ( 19147987 )
2010
Sources

Variations for Bronchiolo-Alveolar Adenocarcinoma

About this section

Cosmic variations for Bronchiolo-Alveolar Adenocarcinoma:

9 (show top 50) (show all 14696)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM7410942 ZSWIM8 lung,NS,carcinoma,adenocarcinoma c.2505G>A p.G835G 10:73799190-73799190 0
2 COSM7411331 ZSWIM5 lung,NS,carcinoma,adenocarcinoma c.2363C>A p.P788H 1:45034398-45034398 0
3 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 0
4 COSM7411164 ZPBP lung,NS,carcinoma,adenocarcinoma c.966C>G p.I322M 7:49937618-49937618 0
5 COSM7411425 ZPBP lung,NS,carcinoma,adenocarcinoma c.706G>T p.V236F 7:50031092-50031092 0
6 COSM2768407 ZNF800 lung,NS,carcinoma,adenocarcinoma c.1606C>T p.R536* 7:127373730-127373730 0
7 COSM7411930 ZNF687 lung,NS,carcinoma,adenocarcinoma c.2361C>G p.H787Q 1:151289161-151289161 0
8 COSM7411692 ZNF608 lung,NS,carcinoma,adenocarcinoma c.2023G>A p.V675I 5:124648361-124648361 0
9 COSM7412390 ZNF536 lung,NS,carcinoma,adenocarcinoma c.2770A>T p.S924C 19:30548389-30548389 0
10 COSM1388126 ZNF521 lung,NS,carcinoma,adenocarcinoma c.2365G>A p.G789S 18:25225553-25225553 0
11 COSM7411528 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1122C>T p.S374S 16:49638030-49638030 0
12 COSM7411524 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1436C>T p.A479V 16:49637716-49637716 0
13 COSM7411526 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1157C>T p.S386F 16:49637995-49637995 0
14 COSM7411530 ZNF423 lung,NS,carcinoma,adenocarcinoma c.634C>A p.H212N 16:49638518-49638518 0
15 COSM3712145 ZNF423 lung,NS,carcinoma,adenocarcinoma c.609C>G p.F203L 16:49638543-49638543 0
16 COSM7411916 ZNF326 lung,NS,carcinoma,adenocarcinoma c.544G>A p.E182K 1:90007679-90007679 0
17 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 0
18 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 0
19 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 0
20 COSM7412277 ZIC5 lung,NS,carcinoma,adenocarcinoma c.1583G>A p.C528Y 13:99965786-99965786 0
21 COSM7411445 ZHX1 lung,NS,carcinoma,adenocarcinoma c.1640C>T p.T547M 8:123254307-123254307 0
22 COSM7411890 ZFX lung,NS,carcinoma,adenocarcinoma c.919C>T p.Q307* 23:24207834-24207834 0
23 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 0
24 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 0
25 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 0
26 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 0
27 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 0
28 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 0
29 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 0
30 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 0
31 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 0
32 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 0
33 COSM6931279 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1530G>T p.E510D 16:72958616-72958616 0
34 COSM6964729 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5670G>C p.Q1890H 16:72797012-72797012 0
35 COSM6935718 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 0
36 COSM6929247 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8677G>C p.G2893R 16:72794005-72794005 0
37 COSM6945078 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 0
38 COSM6935881 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1352G>T p.C451F 16:72958794-72958794 0
39 COSM6940635 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 0
40 COSM6969446 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 0
41 COSM6926443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10885C>G p.P3629A 16:72787391-72787391 0
42 COSM6968693 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 0
43 COSM6962405 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 0
44 COSM6970007 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 0
45 COSM6977567 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 0
46 COSM5796563 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.445C>T p.Q149* 16:72959701-72959701 0
47 COSM6966467 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5788T>C p.S1930P 16:72796894-72796894 0
48 COSM6970295 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 0
49 COSM6968715 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 0
50 COSM6145051 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.562G>T p.A188S 16:72959584-72959584 0
Sources

Expression for Bronchiolo-Alveolar Adenocarcinoma

About this section
Search GEO for disease gene expression data for Bronchiolo-Alveolar Adenocarcinoma.
Sources

Pathways for Bronchiolo-Alveolar Adenocarcinoma

About this section

Pathways related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Gastric cancer 38
Show member pathways
 12.29 CDH1 CDX2 EGFR KRAS
2
Glioma 38
Show member pathways
 12.26 CDH1 EGFR FHIT KRAS
3
Colorectal Cancer Metastasis 65
11.8 CDH1 EGFR KRAS
4
Integrated Breast Cancer Pathway 1
11.62 CDH1 EGFR KRAS
5
Bladder cancer 1 38
11 CDH1 EGFR KRAS
6
a6b1 and a6b4 Integrin signaling 1
10.99 CDH1 EGFR
7
Extracellular vesicle-mediated signaling in recipient cells 1
10.95 EGFR KRAS
8
G-protein signaling_K-RAS regulation pathway 23
10.89 EGFR KRAS
9
EGFR Transactivation by Gastrin 67
Show member pathways
 10.85 EGFR KRAS
10
Preimplantation Embryo 1
10.58 CDH1 CDX2 NKX2-1
11
E-cadherin signaling in keratinocytes 1
10.43 CDH1 EGFR
Sources

GO Terms for Bronchiolo-Alveolar Adenocarcinoma

About this section

Biological processes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pituitary gland development GO:0021983 9.37 CDH1 NKX2-1
2 epithelial tube branching involved in lung morphogenesis GO:0060441 9.32 KRAS NKX2-1
3 maintenance of gastrointestinal epithelium GO:0030277 9.26 MUC4 MUC6
4 cerebral cortex cell migration GO:0021795 9.16 EGFR NKX2-1
5 pattern specification process GO:0007389 9.13 ASPH CDX2 NKX2-1
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.8 KRAS MUC4 MUC6
Sources

Sources for Bronchiolo-Alveolar Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....